Cowen Inc. lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 46.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,700 shares of the biopharmaceutical company’s stock after selling 5,000 shares during the quarter. Cowen Inc.’s holdings in Alnylam Pharmaceuticals were worth $670,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ALNY. QS Investors LLC grew its position in Alnylam Pharmaceuticals by 59.7% in the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 900 shares during the period. The Manufacturers Life Insurance Company grew its position in Alnylam Pharmaceuticals by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 167 shares during the period. CIBC Asset Management Inc purchased a new position in Alnylam Pharmaceuticals in the second quarter worth approximately $221,000. Neuberger Berman Group LLC purchased a new position in Alnylam Pharmaceuticals in the second quarter worth approximately $229,000. Finally, Fayerweather Charles purchased a new position in Alnylam Pharmaceuticals in the third quarter worth approximately $230,000. 88.43% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently weighed in on the company. JMP Securities increased their price objective on Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 20th. Barclays increased their price objective on Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 8th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $110.00 price objective (down from $126.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. FBR & Co assumed coverage on Alnylam Pharmaceuticals in a research report on Monday, October 30th. They set a “buy” rating and a $150.00 price target for the company. Finally, Cowen restated an “outperform” rating and set a $151.00 price target (up from $117.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $121.85.

In related news, CEO John Maraganore sold 73,415 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $130.90, for a total value of $9,610,023.50. Following the completion of the transaction, the chief executive officer now directly owns 223,125 shares in the company, valued at $29,207,062.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Laurie Keating sold 30,000 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, December 1st. The shares were sold at an average price of $135.89, for a total value of $4,076,700.00. Following the completion of the transaction, the senior vice president now owns 41,500 shares of the company’s stock, valued at $5,639,435. The disclosure for this sale can be found here. Over the last quarter, insiders sold 393,212 shares of company stock valued at $48,109,436. 4.30% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at $130.89 on Friday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $35.98 and a fifty-two week high of $147.63. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The company had revenue of $17.10 million during the quarter, compared to analysts’ expectations of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The company’s revenue for the quarter was up 24.8% on a year-over-year basis. During the same quarter last year, the business posted ($1.21) earnings per share. sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -5.21 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/cowen-inc-sells-5000-shares-of-alnylam-pharmaceuticals-inc-alny/1753793.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.